Navigation Links
Cynosure Expands Presence in China with the Opening of Sales Office in Beijing
Date:6/25/2008

WESTFORD, Mass., June 25 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today announced the opening of its second sales office in the People's Republic of China. Located in the Chao Yang District of Beijing, the office will be headed by Aileen Ren, vice general manager of sales and marketing for Cynosure China, the company's wholly owned subsidiary. Cynosure also has a sales office in Suzhou, located approximately an hour northwest of Shanghai.

"Consistent with our strategy, we are continuing to broaden the global reach of our newest aesthetic laser systems in key international markets," said President and Chief Executive Officer Michael Davin. "China, with its rapidly growing affluent middle class and the world's largest population, is an important region for Cynosure. We have operated in the People's Republic since 1995 and in 2006 we became the first U.S. aesthetic laser company to establish a wholly owned subsidiary there. Following on the successful introduction of our Elite(TM) family of workstations in China last year, we are continuing to pursue additional regulatory approvals of our flagship products for this expanding market."

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Safe Harbor

This press release about future expectations, plans and prospects for Cynosure in the People's Republic of China includes forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements contain the words "believes," "anticipates," plans," "expects," "will" and similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Cynosure's history of operating losses, its reliance on sole source suppliers, the inability to accurately predict Cynosure's success in China, changes in consumer preferences, competition in the aesthetic laser industry, as well as economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward- looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

617.542.5300

cyno@investorrelations.com


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cynosure to Present at the Maxim Group Growth Conference
2. Cynosure to Announce Third-Quarter 2007 Financial Results on November 1
3. Cynosure Files Patent Infringement Lawsuit Against CoolTouch Inc.
4. CoolTouch Inc. Responds to Cynosure Patent Infringement Lawsuit
5. Cynosure Launches Three Aesthetic Products at American Academy of Dermatology 2008 Annual Meeting
6. Cynosure to Announce First-Quarter 2008 Financial Results on April 29
7. Cynosures Accolade(TM) Workstation for Pigmented Lesions Receives Korean Regulatory Approval
8. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
9. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
10. Rohm and Haas Expands in India
11. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community ... will return to the La Gorce Country Club in Miami Beach to host ...
(Date:2/23/2017)... ... 2017 , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will ... to Hot,” which will begin airing on February 24, 2017. The show chronicles the ... 2012 reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC ...
(Date:2/23/2017)... IPSWICH, Mass. (PRWEB) , ... February 23, 2017 ... ... chosen as an approved content provider for the National Institute for Health ... care and social care-related organizations in the National Health Service (NHS) to search, ...
(Date:2/23/2017)... Denver, Colorado (PRWEB) , ... February 23, 2017 ... ... Dialog Magazine, an exciting, new, interactive publication where generations converge and explore the ... to expand their worldview, Dialog Magazine enables readers to gain understanding, increase empathy, ...
(Date:2/23/2017)... ... 23, 2017 , ... Healthcare Research & Analytics® (HRA®) in ... against cancer, has produced a seminal study that asked cancer survivors and their ... in a webinar, Defining Compassionate Care Through the Voices of Patients and Advocates ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and ... Devices Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 9.2% over the next decade ... report analyzes the market estimates and forecasts for all the given ...
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... MBVX), a clinical-stage oncology drug development company, announces ... Food and Drug Administration (FDA) authorizing the initiation ... a therapeutic treatment for pancreatic cancer. MVT-1075 ( ... antibody radioimmunotherapy (RIT). MabVax plans to initiate the ...
(Date:2/23/2017)... Orthopedic and cardiac devices will continue ... patterns lead to an increasing prevalence of musculoskeletal ... injuries, chronic back problems, heart valve replacement, and ... future of medical implants faces many uncertainties. ... more: - What types of medical implants ...
Breaking Medicine Technology: